

**(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)**  
**Government of India**  
**Ministry of Chemicals and Fertilizers**  
**Department of Pharmaceuticals**  
**National Pharmaceutical Pricing Authority**  
**New Delhi**

**Dated: 31<sup>st</sup> March, 2017**

**Addendum**

**SO.No 1029(E)** In continuation of National Pharmaceutical Pricing Authority's Order S.O. 412(E) dated 13<sup>th</sup> February, 2017, published in the Gazette of India, Extraordinary, related to ceiling price fixation of Coronary Stents under paragraph 19 of the Drugs (Price Control) Order (DPCO), 2013, notes (l), (m), (n) and (o) are hereby inserted after note (k) of para 12 of abovesaid order, as follows:

*(l) The ceiling prices specified in Para 12 of this order shall also apply to 'Covered Coronary Stents'.*

*(m) The ceiling prices as specified in Para 12 of the order are inclusive of maximum 8% trade margin which is sacrosanct and no additional charge, whatsoever, over and above the ceiling price specified hereinabove, in the price notification shall be charged from the consumer/patient except applicable local taxes/VAT, if any, paid in actual or payable.*

*(n) The inter-se distribution of abovesaid 8% trade margin could be decided by the stent manufacturers/importers, as the case may be, depending upon their business model.*

*(o) Trade margin in excess of 8% specified above, in whatsoever form, shall be construed as 'violation' by the 'person/institutions/manufacturers/importers/distributors/hospitals' involved in the transactions, jointly and severally, and shall be liable to appropriate action including prosecution, for violation of the provisions of the DPCO, 2013 under the Essential Commodities Act, 1955.*

[P N/175/43/2017/F. No. 8(43)/2017/DP/NPPA/DIV.II]

(A.K. Khurana)  
Director